Israel Englander Rubius Therapeutics, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $0.31 $7,727 - $17,109	-55,193 Reduced 24.56%	169,571 $29,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $316,568 - $887,768	-688,193 Reduced 75.38%	224,764 $98,000
Q2 2022 Aug 15, 2022	BUY	$0.79 - $5.98 $309,269 - $2.34 Million	391,481 Added 75.07%	912,957 $777,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $1.99 Million - $4.88 Million	469,027 Added 894.25%	521,476 $2.87 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $312,770 - $573,197	32,311 Added 160.45%	52,449 $508,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $1.49 Million - $2.2 Million	-84,755 Reduced 80.8%	20,138 $360,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $2.1 Million - $2.68 Million	94,154 Added 876.75%	104,893 $2.56 Million
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $242,524 - $967,982	-30,240 Reduced 73.79%	10,739 $285,000
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $136,053 - $280,791	-32,164 Reduced 43.97%	40,979 $311,000
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $340,114 - $457,143	73,143 New	73,143 $366,000
Q2 2020 Aug 14, 2020	SELL	$4.01 - $6.88 $72,801 - $124,906	-18,155 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$3.74 - $9.84 $847,110 - $2.23 Million	-226,500 Reduced 92.58%	18,155 $81,000
Q4 2019 Feb 14, 2020	BUY	$7.23 - $14.12 $1.34 Million - $2.61 Million	184,836 Added 308.99%	244,655 $2.32 Million
Q3 2019 Nov 14, 2019	SELL	$7.85 - $15.75 $243,224 - $487,998	-30,984 Reduced 34.12%	59,819 $469,000
Q2 2019 Aug 15, 2019	BUY	$13.5 - $19.94 $1.23 Million - $1.81 Million	90,803 New	90,803 $1.43 Million

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account